Stephanie Reid

Stephanie Reid supports the Centers for Disease Control and Prevention’s Office of Acquisition Services in executing mission-critical procurement activities that enable public health preparedness and scientific response. She manages a diverse portfolio of acquisitions focused on laboratory diagnostics, biomedical research infrastructure, and data-driven surveillance systems, ensuring timely access to technologies and services critical to infectious disease detection and outbreak response. Her work directly supports CDC’s operational readiness by securing high-integrity analytical tools, clinical testing capabilities, and research support services aligned with national health security priorities. Reid maintains consistent partnerships with leading providers in the life sciences and public health sectors, including General Dynamics Information Technology, GlaxoSmithKline, MRIGLOBAL, and Cepheid. These relationships center on complex, high-stakes procurements involving advanced diagnostic platforms, laboratory instrumentation, and bioanalytical services. Her contracting approach emphasizes technical rigor, compliance with federal acquisition regulations, and long-term vendor collaboration to ensure continuity of critical public health functions during evolving health threats. Her procurement patterns reflect a strong preference for full and open competition, with 94.1% of awards issued without set-aside restrictions. While small business participation is limited, she consistently engages total small business set-asides under FAR 19.5, demonstrating a measured but intentional commitment to expanding vendor diversity within technically demanding categories where qualified small firms are scarce. Reid’s primary procurement focus lies in NAICS 541715 (research and development in life sciences), 334516 (analytical laboratory instrument manufacturing), and 541380 (testing laboratories and services). She routinely acquires next-generation PCR systems, biosafety equipment, clinical data analytics platforms, and precision diagnostic instruments, requiring deep technical fluency in molecular biology, clinical validation protocols, and FDA-regulated medical devices. Her expertise ensures CDC’s laboratory and surveillance networks remain at the forefront of global public health innovation.